John C Kessler

Address:

4345 Woodstream Dr, Ypsilanti, MI 48197

VIN:

2LMHJ5AT0ABJ03778

Make:

LINCOLN

Model:

MKT

Year:

2010

US Patent:

20050214257, Sep 29, 2005

Filed:

Dec 21, 2004

Appl. No.:

11/018622

Inventors:

Li-Ru Zhao - Naperville IL, US
John Kessler - Chicago IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K045/00
A61K038/08

US Classification:

424093200, 514017000, 424093700

Abstract:

The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.

US Patent:

20060247165, Nov 2, 2006

Filed:

Jan 23, 2006

Appl. No.:

11/337316

Inventors:

Samuel Stupp - Chicago IL, US
John Kessler - Chicago IL, US

International Classification:

A61K 38/18
A61K 38/08

US Classification:

514012000, 514017000

Abstract:

The present invention relates to methods and compositions for altering (e.g., augmenting or stimulating) differentiation and growth of cells (e.g., neural progenitor cells and neurons). In particular, the present invention relates to compositions comprising one or more self-assembling peptide amphiphiles (e.g., in solution or that generate (e.g., self-assemble into) nanofibers (e.g., that are able to encapsulate cells and promote cellular differentiation (e.g., neurite development))) and methods of using the same. Compositions and methods of the present invention find use in research, clinical (e.g., therapeutic) and diagnostic settings.

US Patent:

20120237484, Sep 20, 2012

Filed:

Jul 8, 2011

Appl. No.:

13/178734

Inventors:

Christopher Bissonnette - Chicago IL, US
John Kessler - Chicago IL, US

International Classification:

C12N 5/0793
A61P 25/28
A61P 25/00
C12N 15/85
A61K 35/30

US Classification:

424 937, 435377, 435455

Abstract:

The present invention provides method, compositions, and systems for generating basal forebrain cholinergic neurons (BFCNs) using FGF8, SHH, LXH8, GBX1, or vectors encoding these ligands, as well as using such BFCNs to treat neurological disorders such as Alzheimer's disease.

US Patent:

20210047413, Feb 18, 2021

Filed:

Aug 17, 2020

Appl. No.:

16/995392

Inventors:

- Evanston IL, US
John A. Kessler - Chicago IL, US

International Classification:

C07K 16/28
A61K 38/16
A61P 19/00

Abstract:

Disclosed are methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof. Particularly disclosed are methods for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof by administering to the subject a therapeutic agent such as an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof.